文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

硒代蛋氨酸通过抑制ROS/NLRP3信号减轻脓毒症诱导的骨骼肌萎缩

Selenomethionine Attenuates Sepsis-Induced Skeletal Muscle Atrophy by Inhibiting ROS/NLRP3 Signaling.
PubMed 文献 · Shock · 2025-09-04
一句话结论小鼠脓毒症模型中,硒代蛋氨酸通过抗氧化、抑制细胞焦亡减轻骨骼肌萎缩并改善生存、体重与肌力,为脓毒症相关肌损伤提供实验依据。

该研究建立盲肠结扎穿孔小鼠脓毒症模型,给予不同剂量硒代蛋氨酸治疗,评估生存率、体重、骨骼肌质量与肌力,并用HE染色评估肌纤维横截面积。结果显示硒代蛋氨酸显著改善脓毒症小鼠生存、体重和肌力,减轻骨骼肌萎缩。机制上,硒代蛋氨酸抑制NLRP3/Caspase-1/GSDMD信号轴,减少细胞焦亡及IL-6、IL-18、IL-1β等炎症因子表达;同时降低ROS蓄积、增强抗氧化酶活性,并通过调控ROS/NLRP3通路抑制焦亡,最终减少Atrogin-1和MuRF1介导的蛋白降解。体外C2C12肌母细胞经脂多糖刺激后,硒代蛋氨酸同样减轻氧化应激与焦亡相关蛋白及炎症因子表达,机制研究中使用ROS清除剂N-乙酰半胱氨酸、NLRP3激动剂和ROS诱导剂进一步阐明通路。

要点

  • 小鼠盲肠结扎穿孔脓毒症模型中,硒代蛋氨酸显著改善生存率、体重和肌力,并减轻骨骼肌萎缩。
  • 硒代蛋氨酸抑制NLRP3/Caspase-1/GSDMD信号轴,减少细胞焦亡及IL-6、IL-18、IL-1β等炎症因子表达。
  • 硒代蛋氨酸降低ROS蓄积、增强抗氧化酶活性,通过调控ROS/NLRP3通路减少Atrogin-1和MuRF1介导的蛋白降解。
  • 体外C2C12肌母细胞经脂多糖刺激后,硒代蛋氨酸减轻氧化应激标志物、焦亡相关蛋白及炎症细胞因子表达。
  • 机制研究中使用ROS清除剂N-乙酰半胱氨酸、NLRP3激动剂和ROS诱导剂进一步验证ROS/NLRP3通路的作用。

适用人群与场景

  • 小鼠脓毒症模型(盲肠结扎穿孔法)及体外经脂多糖刺激的C2C12肌母细胞。

处置流程与药物剂量

  • 动物实验中对脓毒症小鼠给予不同剂量硒代蛋氨酸治疗,具体剂量原文未写明。
  • 体外实验中对脂多糖刺激的C2C12肌母细胞给予硒代蛋氨酸处理,具体浓度原文未写明。
  • 机制研究中使用ROS清除剂N-乙酰半胱氨酸、NLRP3激动剂和ROS诱导剂。

研究设计与关键结果

  • 研究类型为动物实验(小鼠盲肠结扎穿孔脓毒症模型)结合体外细胞实验,样本量原文未写明。
  • 硒代蛋氨酸显著改善脓毒症小鼠生存率、体重和肌力,并减轻骨骼肌萎缩(具体数值原文未写明)。
  • 硒代蛋氨酸抑制NLRP3/Caspase-1/GSDMD信号轴,减少细胞焦亡及IL-6、IL-18、IL-1β表达(具体数值原文未写明)。
  • 硒代蛋氨酸降低ROS蓄积、增强抗氧化酶活性,减少Atrogin-1和MuRF1介导的蛋白降解(具体数值原文未写明)。

证据类型、等级与局限

  • 证据类型:动物实验与体外细胞实验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,硒代蛋氨酸通过抗氧化、抑制焦亡和调节炎症反应减轻脓毒症诱导的骨骼肌萎缩,为脓毒症及其他氧化应激相关疾病的潜在应用提供新的实验证据。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: Sepsis-induced muscle atrophy significantly impairs patient quality of life, yet effective therapeutic strategies remain limited. This study aimed to investigate the protective effects of selenomethionine (Se-Met) on sepsis-induced skeletal muscle atrophy and explore the underlying molecular mechanisms, with the goal of providing a novel theoretical foundation and potential therapeutic approach for sepsis-associated muscle injury.

METHODS: A murine sepsis model was established via cecal ligation and puncture, followed by treatment with varying doses of Se-Met. Survival rate, body weight, skeletal muscle mass, and muscle strength were evaluated. Histological analysis [hematoxylin and eosin (HE) staining] was used to assess muscle fiber cross-sectional area. Protein expression levels of Atrogin-1, MuRF1, and pyroptosis-related markers (NLRP3, Caspase-1, GSDMD, IL-18, and IL-1β) were examined via Western blot. In vitro , C2C12 myoblasts were stimulated with lipopolysaccharide and treated with Se-Met to assess oxidative stress markers [reactive oxygen species (ROS), malondialdehyde, superoxide dismutase, glutathione peroxidase], pyroptosis-related proteins, and inflammatory cytokines (e.g., IL-6 and IL-18). ROS scavenger N-acetylcysteine, NLRP3 agonist, and ROS inducer were employed in mechanistic studies to further elucidate the molecular mechanisms.

RESULTS: Se-Met significantly improved survival, body weight, and muscle strength in septic mice and alleviated skeletal muscle atrophy. Mechanistically, Se-Met inhibited the NLRP3/Caspase-1/GSDMD signaling axis, thereby reducing pyroptosis and the expression of inflammatory cytokines such as IL-6, IL-18, and IL-1β. Furthermore, Se-Met decreased ROS accumulation, enhanced antioxidant enzyme activities, and suppressed pyroptosis through regulation of the ROS/NLRP3 pathway, ultimately reducing protein degradation mediated by Atrogin-1 and MuRF1.

CONCLUSION: This study demonstrates that Se-Met mitigates sepsis-induced skeletal muscle atrophy by exerting antioxidant effects, inhibiting pyroptosis, and modulating inflammatory responses. The findings highlight the critical role of the ROS/NLRP3 signaling pathway in the protective action of Se-Met, providing new experimental evidence for its potential application in sepsis and other oxidative stress-related diseases.

来源:Shock,查看原文。版权归原作者所有。

参考来源

  1. Li T, Zhao X, Xu Z, et al. Selenomethionine Attenuates Sepsis-Induced Skeletal Muscle Atrophy by Inhibiting ROS/NLRP3 Signaling. Shock. 2025. PMID: 40961381. doi:10.1097/SHK.0000000000002690

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。